Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 31

Trial Status

Recruiting1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT06589804Phase 3Recruiting
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell Carcinoma+18 more
PrincipalinvestigatorStart date: 2025-03-27

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Siwen Hu-Lieskovan

SWOG Cancer Research Network

Related
2 trials

Shared therapeutic areas:

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell Carcinoma+6 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score13%

George Blumenschein, MD

M.D. Anderson Cancer Center

Related
5 trials

Shared therapeutic areas:

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell Carcinoma+3 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score9%

Nabil F. Saba, MD

Emory University

Related
2 trials

Shared therapeutic areas:

Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell Carcinoma+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score7%

Athanassios (Ethan) Argiris

ECOG-ACRIN Cancer Research Group

Related
2 trials

Shared therapeutic areas:

Recurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Neck Squamous Cell Carcinoma of Unknown Primary+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score6%

Kathryn M. Van Abel, MD

Mayo Clinic in Rochester

Related
2 trials

Shared therapeutic areas:

Metastatic Oropharyngeal Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaStage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Similarity Score4%

Eileen H Shinn

M.D. Anderson Cancer Center

Related
2 trials

Shared therapeutic areas:

Stage IV Hypopharyngeal Carcinoma AJCC v8Stage IV Laryngeal Cancer AJCC v8Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score4%

Roxana S. Dronca, M.D.

Mayo Clinic

Related
2 trials

Shared therapeutic areas:

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Similarity Score3%

Mojun Zhu, M.D.

Mayo Clinic in Rochester

Related
2 trials

Shared therapeutic areas:

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Similarity Score3%

Hassan Arshad

Roswell Park Cancer Institute

Related
3 trials

Shared therapeutic areas:

Recurrent Laryngeal Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Douglas Adkins, M.D.

Washington University School of Medicine

Related
11 trials

Shared therapeutic areas:

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT06589804Phase 3PrincipalInvestigator

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell Carcinoma+18 more
Recruiting

All 1 trials loaded